Abstract
The present treatment of advanced and metastatic medullary thyroid carcinoma (MTC) is unsatisfactory. Tissue-specific cancer gene therapy is a novel alternative approach. We developed a recombinant adenovirus expressing Herpes simplex type 1 thymidine kinase (HSVtk) driven by a modified CALC-I promoter TCP (AdTCPtk). Infection with this virus showed efficient cytotoxic effect on MTC cell lines (rMTC and TT cells) after treatment with ganciclovir (GCV) in vitro. In a syngenic WAG/Rij rat model, the combination of AdTCPtk/GCV treatment with administration of murine interleukin-12 (mIL-12) expressing adenovirus under control of TCP (AdTCPmIL-12) resulted in effective growth suppression of tumor at the treated site and also at a distant untreated site, in comparison to treatment with AdTCPtk/GCV or AdTCPmIL-12 alone. Moreover, intravenous injection of AdTCPtk, or AdTCPtk+AdTCPmIL-12, followed by administration of GCV, did not cause evident toxicity after administration of GCV. These results indicate that this combined system can provide an effective therapy for metastatic MTC with minimal toxicity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Vitale G, Caraglia M, Ciccarelli A, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer. 2001;91:1797–1808.
Stone D, David A, Bolognani F, et al. Viral vectors for gene delivery and gene therapy within the endocrine system. J Endocrinol. 2000;164:103–118.
Deonarain MP, Spooner RA, Epenetos AA . Genetic delivery of enzymes for cancer therapy. Gene Therapy. 1995;2:235–244.
Beltinger C, Fulda S, Kammertoens T, et al. Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis. Cancer Res. 2000;60:3212–3217.
Drake RR, Pitlyk K, McMasters RA, et al. Connexin-independent ganciclovir-mediated killing conferred on bystander effect-resistant cell lines by a herpes simplex virus-thymidine kinase-expressing colon cell line. Mol Ther. 2000;2:515–523.
Mesnil M, Piccoli C, Tiraby G, et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93:1831–1835.
Mesnil M, Yamasaki H . Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 2000;60:3989–3999.
Rodolfo M, Colombo MP . Interleukin-12 as an adjuvant for cancer immunotherapy. Methods. 1999;19:114–120.
Colombo MP, Trinchieri G . Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13:155–168.
Tang Z, Sun W, Chen S . Combination therapy of murine liver cancer with IL-12 gene and HSV-TK gene. Zhonghua Zhong Liu Za Zhi. 1999;21:332–335.
Drozdzik M, Qian C, Xie X, et al. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma. J Hepatol. 2000;32:279–286.
Hall SJ, Canfield SE, Yan Y, et al. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer. Gene Therapy. 2002;9:511–517.
Lechanteur C, Delvenne P, Princen F, et al. Combined suicide and cytokine gene therapy for peritoneal carcinomatosis. Gut. 2000;47:343–348.
Nasu Y, Bangma CH, Hull GW, et al. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer Prostatic Dis. 2001;4:44–55.
Toda M, Martuza RL, Rabkin SD . Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Therapy. 2001;8:332–339.
Lohr F, Huang Q, Hu K, et al. Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. Clin Cancer Res. 2001;7:3625–3628.
Brand K, Arnold W, Bartels T, et al. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther. 1997;4:9–16.
van der Eb MM, Cramer SJ, Vergouwe Y, et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Therapy. 1998;5:451–458.
Brand K, Loser P, Arnold W, et al. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Therapy. 1998;5:1363–1371.
Nettelbeck DM, Jerome V, Muller R . Gene therapy: designer promoters for tumour targeting. Trends Genet. 2000;16:174–181.
Minemura K, Takeda T, Nagasawa T, et al. Cell-specific induction of sensitivity to ganciclovir in medullary thyroid carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Endocrinology. 2000;141:1814–1822.
Yamazaki M, Zhang R, Straus FH, et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Therapy. 2002;9:64–74.
DeGroot LJ, Zhang R . Clinical review 131: gene therapy for thyroid cancer: where do we stand? J Clin Endocrinol Metab. 2001;86:2923–2928.
Peleg S . Modified binding of proteins from calcitonin-negative tumor cells to the neuroendocrine-specific CANNTG motif of the calcitonin gene. Nucleic Acids Res. 1993;21:5360–5365.
Messina M, Yu DM, Learoyd DL, et al. High level, tissue-specific expression of a modified calcitonin/calcitonin gene-related peptide promoter in a human medullary thyroid carcinoma cell line. Mol Cell Endocrinol. 2000;164:219–224.
Russwurm S, Stonans I, Stonane E, et al. Procalcitonin and CGRP-1 mrna expression in various human tissues. Shock. 2001;16:109–112.
Bracq S, Taboulet J, Machairas M, et al. Calcitonin mRNA is produced in liver by two different splicing pathways. Mol Cell Endocrinol. 1997;128:111–115.
Elshami AA, Cook JW, Amin KM, et al. The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo. Cancer Gene Ther. 1997;4:213–221.
Beck C, Cayeux S, Lupton SD, et al. The thymidine kinase/ganciclovir-mediated "suicide" effect is variable in different tumor cells. Hum Gene Ther. 1995;6:1525–1530.
Maron A, Havaux N, Le Roux A, et al. Differential toxicity of ganciclovir for rat neurons and astrocytes in primary culture following adenovirus-mediated transfer of the HSVtk gene. Gene Therapy. 1997;4:25–31.
Melcher A, Todryk S, Hardwick N, et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med. 1998;4:581–587.
Todryk S, Melcher AA, Hardwick N, et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol. 1999;163:1398–1408.
Vile RG, Castleden S, Marshall J, et al. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer. 1997;71:267–274.
Soler MN, Milhaud G, Lekmine F, et al. Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes. Cancer Immunol Immunother. 1999;48:91–99.
Green DR, Beere HM . Apoptosis. Gone but not forgotten. Nature. 2000;405:28–29.
Serazin-Leroy V, Denis-Henriot D, Morot M, et al. Semi-quantitative RT-PCR for comparison of mRNAs in cells with different amounts of housekeeping gene transcripts. Mol Cell Probes. 1998;12:283–291.
Acknowledgements
This work was supported by a Center of Excellence award from Knoll Pharmaceuticals, and by the David Wiener Research Fund.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamazaki, M., Straus, F., Messina, M. et al. Adenovirus-mediated tumor-specific combined gene therapy using Herpes simplex virus thymidine/ganciclovir system and murine interleukin-12 induces effective antitumor activity against medullary thyroid carcinoma. Cancer Gene Ther 11, 8–15 (2004). https://doi.org/10.1038/sj.cgt.7700636
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700636
Keywords
This article is cited by
-
Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm
Journal of Experimental & Clinical Cancer Research (2014)
-
Gene therapy with tumor-specific promoter mediated suicide gene plus IL-12 gene enhanced tumor inhibition and prolonged host survival in a murine model of Lewis lung carcinoma
Journal of Translational Medicine (2011)
-
Technology Insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma
Nature Clinical Practice Endocrinology & Metabolism (2007)
-
Study of calcitonin and calcitonin gene— related peptide in patients with medullary thyroid carcinoma
Chinese Journal of Clinical Oncology (2005)